Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. (TERN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
tern · stock forecast · 16 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 16 Wall Street analysts in the past 3 months
Buy
16 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$70.00
Consensus
$58.13
+9.8% upside
Low
$53.00
Median: $57 · Last Close: $52.95
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$58.13
9.8% upside
High Target
$70
32.2%
Low Target
$53
0.1%
Current Price
$52.95
as of today
Based on analyst price targets, the TERN stock price prediction for the next 12 months ranges from $53 to $70. The consensus TERN price forecast of $58.13 implies 9.8% upside from the current price of $52.95.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $52.88 | ↓ 0.14% |
1-day model range: $52.86–$52.89. Peak: $52.89 (-0.14%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TERN · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-27 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2026-04-14 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-03-31 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2026-03-30 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2026-03-26 | Citizens | Downgrade ↓ | Market Outperform→Market Perform |
| 2026-03-26 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2026-03-25 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-12-11 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2025-12-09 | Barclays | Maintains | Overweight→Overweight |
| 2025-12-09 | Mizuho | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Terns Pharmaceuticals, Inc. (TERN) stock. Of the recent 79 rating actions, 2 were upgrades and 7 were downgrades. 16 analysts currently cover TERN.
Analyst Recommendation Trends
TERN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 91.9% YoY
Revenue Next Year
$6M
↑ 500.7% YoY
EPS This Year
$-1.16
EPS Next Year
$-1.43
↑ 23.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast TERN EPS of $-1.16 for the current fiscal year, based on estimates from 3 analysts. The TERN revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TERN stock forecast is supported by two independent data sources: analyst consensus ratings from 16 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TERN price target is $58.13 (+9.8% upside), with an analyst consensus of Buy.
The TERN short-term stock prediction for tomorrow is $52.88 (-0.14%).
Terns Pharmaceuticals, Inc. trades on NASDAQ under the ticker TERN. The TERN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.
Frequently asked questions
TERN forecast · 8 questionsAccording to 16 Wall Street analysts, the average 12-month TERN price target is $58.13, with a high forecast of $70.00 and a low of $53.00. The median price target is shown in the chart above when available. This implies +9.8% potential upside from the current price of $52.95.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.